Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of...
43 insider purchases on record · latest filing 2025-05-19.
Insiders have also filed 131 sale transactions at CNTA.